Advertisement

Bayesian Dose Escalation Study Design with Consideration of Both Early and Late Onset Toxicity

  • Li LiuEmail author
  • Lei Gao
  • Glen Laird
Chapter
Part of the ICSA Book Series in Statistics book series (ICSABSS)

Abstract

In phase I oncology trials, dose-limiting toxicity (DLT) is often used as the endpoint during early cycles in dose escalation studies to find the maximum tolerated dose (MTD). Bayesian adaptive designs such as the Escalation with Overdose Control (EWOC; Babb et al., Stat Med 17:1103–1120, 1998) methods have been introduced to protect patients from overdosing and account for variability in toxicity estimates.

Because of the short term nature of the DLT endpoint, these methods may not be feasible in practice when a particular adverse event is likely to occur during longer term exposure. To accommodate a longer assessment time while maintaining escalation timelines, Tighiouart et al. (PLoS One 9(3):e93070, 2014) proposed an EWOC design using a time to event toxicity endpoint.

When both early and late onset toxicity are crucial for dose finding studies, we propose to define DLT with two components, one for immediate toxicity in a binary model, and the other for late onset toxicity in a time to event model. The types of immediate toxicity and late onset toxicity are different. Through simulations, we demonstrated that the proposed dose escalation design can incorporate historical knowledge, protect patients from being assigned to toxic doses, and consider early and late onset toxicity while maintaining the escalation timeline. This design has been implemented in a phase 1 dose escalation study with both short term DLT and long term AESI, which allowed the study team to consider both the short term DLT and long term AESI with an acceptable timeline.

Keywords

Dose escalation study Late onset toxicity Early and late onset toxicities Escalation with overdose control Time to event toxicity endpoint Bayesian dose finding 

Notes

Acknowledgement

The authors appreciate the helpful discussions with Mourad Tighiouart and Pierre Colin. The authors thank referees and the associate editor for their excellent comments and suggestions.

References

  1. Babb, J., Rogatko, A., Zacks, S.: Cancer phase I clinical trials: efficient dose escalation with overdose control. Stat. Med. 17, 1103–1120 (1998)CrossRefGoogle Scholar
  2. Berry, S.M., Carlin, B.P., Lee, J.J., Müller, P.: Bayesian Adaptive Methods for Clinical Trials. CRC Press, Boca Raton (2010)CrossRefGoogle Scholar
  3. Braun, T.M.: Generalizing the TITE-CRM to adapt for early- and late-onset toxicities. Stat. Med. 25, 2071–2083 (2006).  https://doi.org/10.1002/sim.23372 MathSciNetCrossRefGoogle Scholar
  4. Cheung, Y., Chappell, R.: Sequential designs for phase I clinical trials with late-onset toxicities. Biometrics. 56, 1177–1182 (2000)MathSciNetCrossRefGoogle Scholar
  5. Cunanan, K., Koopmeiners, J.S.: Evaluating the performance of copula models in phase I-II clinical trials under model misspecification. BMC Med. Res. Methodol. 14, 51 (2014)CrossRefGoogle Scholar
  6. EMA. Guideline on the evaluation of anticancer medicinal products in man. EMA/CHMP/205/95 Rev.5 (2017)Google Scholar
  7. Goodman, S.N., Zahurak, M.L., Piantadosi, S.: Some practical improvements in the continual reassessment method for phase I studies. Stat. Med. 14(11), 1149–1161 (1995)CrossRefGoogle Scholar
  8. Iasonos, A., Wages, N.A., Conaway, M.R., Cheung, K., Yuan, Y., O’Quigley, J.: Dimension of model parameter space and operating characteristics in adaptive dose-finding studies. Stat. Med. 35, 3760–3775 (2016)MathSciNetCrossRefGoogle Scholar
  9. Kummar, S., Gutierrez, M., Doroshow, J.H., Murgo, A.J.: Drug development in oncology: classical cytotoxics and molecularly targeted agents. Br. J. Clin. Pharmacol. 62(1), 15–26 (2006)CrossRefGoogle Scholar
  10. Ma, X., Zheng, W., Lu, Y.: Personalized effective dose selection in dose ranging studies. In: Lin, J., Wang, B., Hu, X., Chen, K., Liu, R. (eds.) Statistical Applications from Clinical Trials and Personalized Medicine to Finance and Business Analytics. Springer, Basel (2016)Google Scholar
  11. Mauguen, A., Le Deley, M.C., Zohar, S.: Dose-finding approach for dose escalation with overdose control considering incomplete observations. Stat. Med. 30(13), 1584–1594 (2011)MathSciNetCrossRefGoogle Scholar
  12. Neuenschwander, B., Branson, M., Gsponer, T.: Critical aspects of the Bayesian approach to phase I cancer trials. Stat. Med. 27, 2420–2439 (2008)MathSciNetCrossRefGoogle Scholar
  13. O’Quigley, J., Pepe, M., Fisher, L.: Continual reassessment method: a practical design for phase 1 clinical trials in cancer. Biometrics. 46, 33–48 (1990).  https://doi.org/10.2307/2531628 MathSciNetCrossRefzbMATHGoogle Scholar
  14. Paoletti, X., Toumeau, C.L., Verweij, J., Siiu, L.L., Seymour, L., Postel-Vinay, S., Collette, L., Rizzo, E., Ivy, P., Olmos, D., Massard, C., Lacombe, D., Kaye, S.B., Soria, J.-C.: Defining dose-liming toxicity for phase 1 trials of molecularly targeted agents: results of a DLT-TARGETT international survey. Eur. J. Cancer. 50(12), 2050–2056 (2014)CrossRefGoogle Scholar
  15. Sverdlov, O., Gao, L.: Phase I/II dose finding designs with efficacy and safety endpoints. In: O’Quigley, J., Iasonos, A., Bornkamp, B. (eds.) Handbook of Methods for Designing, Monitoring, and Analyzing Dose-Finding Trials. CRC Press, Boca Raton (2017)Google Scholar
  16. Tighiouart, M., Liu, Y., Rogatko, A.: Escalation with overdose control using time to toxicity for cancer phase I clinical trials. PLoS One. 9(3), e93070 (2014).  https://doi.org/10.1371/journal.pone.0093070 CrossRefGoogle Scholar
  17. Tighiouart, M., Rogatko, A., Babb, J.: Flexible Bayesian methods for cancer phase I clinical trials. Dose escalation with overdose control. Stat. Med. 24, 2183–2196 (2005)MathSciNetCrossRefGoogle Scholar
  18. Varricchi, G., Galdiero, M.R., Marone, G., Criscuolo, G., Triassi, M., Bonaduce, D., Marone, G., Tocchetti, C.G.: Cardiotoxicity of immune checkpoint inhibitors. ESMO Open. 2(4), e000247 (2017).  https://doi.org/10.1136/esmoopen-2017-0002473 CrossRefGoogle Scholar

Copyright information

© Springer Nature Switzerland AG 2019

Authors and Affiliations

  1. 1.SanofiBridgewaterUSA
  2. 2.VertexBostonUSA

Personalised recommendations